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ABSTRACT (219 words) 
Purpose: To test the hypothesis that cytoreductive nephrectomy (CN) improves 
overall survival (OS) of patients with synchronous metastatic renal cell carcinoma 
(mRCC), who subsequently receive targeted therapies (TT). 
Methods: We identified 261 patients who received TT for synchronous mRCC with or 
without prior CN. To achieve balance in baseline characteristics between groups, we 
used the inverse probability of treatment weighting (IPTW) method. We conducted 
OS analyses, including IPTW-adjusted Kaplan-Meier curves, Cox regression models, 
interaction term, landmark and sensitivity analyses. 
Results: Of the 261 patients, 97 (37.2%) received CN and 164 (62.8%) did not. 
IPTW-adjusted analyses showed a statistically significant OS benefit for patients 
treated with CN (HR=0.63, 95% CI 0.46-0.83, P=0.0015). While there was no 
statistically significant difference in OS at 3 months (P=0.97), 6 months (P=0.67), and 
12 months (P=0.11) from diagnosis, a benefit for the CN group was noted at 18 
months (P=0.005) and 24 months (P=0.004). On interaction term analyses, the 
beneficial effect of CN increased with better performance status (P=0.06), in women 
(P=0.03), and in patients with thrombocytosis (P=0.01).  
Conclusions: IPTW-adjusted analysis of our patient cohort suggests that CN 
improves OS of patients with synchronous mRCC treated with TT. On the whole, the 
survival difference appears after 12 months. Specific subgroups may particularly 
benefit from CN, and these subgroups warrant further investigation in prospective 
trials. 
 
Keywords: nephrectomy; sunitinib; pazopanib; prognosis; survival 
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INTRODUCTION 
Cytoreductive nephrectomy (CN) has been an integral part of a multimodal 
management concept of patients with synchronous metastatic renal cell carcinoma 
(mRCC) treated with cytokines, as two randomised controlled trials demonstrated a 
significant overall survival (OS) advantage before treatment with interferon-alpha-
based therapy [1–3]. Over the past decade, targeted therapies (TT) with VEGF 
receptor tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin (mTOR) 
inhibitors have replaced cytokine treatment and are now the accepted standard of 
care [4, 5]. Since the inception of these agents, both the role of upfront CN and the 
timing of CN have been questioned. Two randomised controlled trials (SURTIME, 
CARMENA) were initiated to investigate the role of CN in conjunction with sunitinib. 
Unfortunately, both trials suffered from significant recruitment problems [6]. Indeed, 
SURTIME was stopped early and did not show a difference in progression-free 
survival at 28 weeks [7], which may in part due to sample size and insufficient 
statistical power. Likewise, there were considerable challenges with patient 
recruitment in CARMENA, and this trial is expected to end 6 years later than 
originally anticipated. Furthermore, there are some concerns that CARMENA may 
only answer the question of whether both trial arms are equivalent rather than 
showing than showing that one arm is superior [6, 8]. Taken together, there is at 
present no level 1/2 evidence regarding the role of CN for mRCC treated with TT. 
While results from these randomised controlled trials are awaited, best evidence for 
clinical practice and hypotheses for future randomised trials are derived from 
retrospective observational studies. Indeed, multi-centric and registry data suggest 
that CN may be associated with a 40% to 55% relative improvement in OS [8–10]. 
Despite multivariable adjustment for measured confounders, a prevailing hypothesis 
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for this large benefit is selection bias. This could randomly favour the CN arm, as 
these patients may be those in a better general condition or those of a more 
favourable prognostic group. However, there are novel statistical methods such as 
inverse probability of treatment weighting (IPTW) and sensitivity analyses without 
assumptions that improve adjustment for measured and unmeasured confounders 
and thus control for selection bias [11]. As such, we sought to compare OS between 
patients undergoing CN and no CN (NCN) for synchronous mRCC at our tertiary care 
centre using these modern statistical approaches.  
 
 
PATIENTS AND METHODS 
Patient population 
For this retrospective single centre study, patients were identified from the 
prospectively maintained Cambridge Oncology Registry. All patients treated with TT 
(VEGFR-TKIs or mTOR inhibitors) for synchronous clear cell and non-clear cell 
mRCC between 2006 and 2017 were identified; those with hereditary RCC 
syndromes, concomitant malignant tumours other than RCC and those who 
underwent complete surgical resection of all metastatic sites were excluded, leaving 
261 patients as the principal study cohort. The decision to recommend a CN was 
based on a multidisciplinary team discussion of oncologists and urologists. Multiple 
variables were taken into consideration, including performance status (PS), tumour 
volume, number and location of metastatic sites, age, co-morbidity, surgical 
operability, expected surgical morbidity, and prognostic group according to initial 
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blood tests. Patients were reviewed in clinic and a joint decision between patient, 
oncologist and urologist was made on whether to proceed with CN prior to TT.  
Data for this study included receipt of CN, age, gender, metastatic sites, type of 
medical therapies and prognostic criteria at the time of diagnosis, i.e. World Health 
Organization (WHO) PS, albumin-corrected serum calcium, haemoglobin, neutrophil 
count, platelet count, and time from diagnosis to targeted therapy [12]. WHO PS was 
then converted to the categorical Karnofsky PS (KPS; i.e. KPS≥80% for WHO PS 0 
or 1, KPS<80% for WHO PS 2-4). Laboratory tests were performed in the 
Addenbrooke’s Hospital laboratory and values were standardised against the upper 
or lower limit of normal, as appropriate [13]. 
 
Statistical analyses 
Temporal trends in the practice pattern of CN were evaluated using a piecewise 
regression approach that is implemented in the Joinpoint Regression Program 
(Version 4.1, National Cancer Institute, Bethesda, MD, United States). In this 
approach, the annual frequency of CN was modelled using a linear segmented 
regression function, with a log-transformed dependent variable. Changes in temporal 
trend of the use of CN are reported as percentage change. 
IPTW-adjusted analyses were performed to account for differences in baseline 
characteristics between groups and thus for selection bias, as popularised by Seisen 
et al. [11]. In this method, each patient was weighted by the inverse probability of 
being in the CN versus NCN group, with the goal of balancing observed 
characteristics between the two groups. The probability (or propensity) of being in the 
two treatment groups was estimated from a logistic regression model that included 
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variables that potentially impacted receipt of CN, i.e. age, presence of lung 
metastasis, liver metastasis, bone metastasis, brain metastasis, lymph node 
metastasis, number of metastatic sites, histological subtype, KPS, anaemia, 
neutrophilia, hypercalcemia, thrombocytosis and year of diagnosis. Baseline 
characteristics were compared between groups pre- and post-weighting using the 
standardised differences approach, as opposed to t tests and χ² tests. In this 
quantitative method, significant imbalances in covariates are present if the 
standardised difference is ≥0.1 (i.e. ≥10%). 
The primary study endpoint was OS, which was calculated from the date of diagnosis 
to death or last follow-up. IPTW-adjusted survivor functions were estimated with the 
Kaplan-Meier method, and overall mortality was compared between groups using 
Cox proportional hazards regression models and IPTW-adjusted log-rank tests. The 
proportional hazards assumption was tested with Schoenfeld tests and 
complementary log-log plots, and demonstrated that this assumption was not violated 
in our models. Exploratory analyses were performed to determine the heterogeneity 
of the CN effect according to baseline variables by testing interaction terms within the 
IPTW-adjusted Cox models.  
In view of the fact that IPTW-weighting balances only measured confounders 
between groups, we performed sensitivity analyses without assumptions to assess 
the impact of unmeasured confounders [14]. According to the approach described by 
Ding and VanderWheele [14], magnitudes of the joint bounding factor were estimated 
for various combinations of the odds of receiving CN in the (ORCN-U) and the hazard 
of overall mortality (HROM-U) both in the presence of unmeasured confounders. All 
statistical analyses were performed with R 3.4.0 (The R Foundation for Statistical 
Computing, Vienna, Austria). Statistical significance was set at 0.05.  
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RESULTS 
Baseline characteristics  
The overall cohort included 261 patients with synchronous mRCC, of whom 97 
(37.2%) underwent CN and 164 (62.8%) did not. The proportion of patients who 
underwent CN decreased over the years, with a biannual change of -11.5% (95% CI -
19.7 to -2.5, P<0.001, Fig. 1). The most common first line TT were sunitinib (N=158, 
60.5%) and pazopanib (N=74, 28.4%). One hundred and twelve patients (42.9%) 
received advanced line treatments (>first line), of which 22 (8.4%) included 
cabozantinib or nivolumab.  
Unweighted and weighted baseline characteristics are presented in Table 1. In 
unweighted comparisons, both groups differed with respect to all analysed baseline 
variables except gender and presence of lung metastases. After IPTW adjustment, all 
standardised differences were <0.1, indicating that both groups were then 
comparable. 
 
Overall survival 
There were 206 deaths (78.9%) during follow-up. The median follow-up for patients 
surviving was 14.6 months (IQR 7.1 to 24.3). In unadjusted analyses, overall 
mortality was reduced in relative terms by 54% in the CN group (HR 0.46, 95% CI 
0.34 to 0.62, P<0.001), with a median OS time of 25.6 months (95% CI 23.3 to 32.1) 
versus 12.4 months (95% CI 10.3 to 15.0, Fig. 2A). In IPTW-adjusted analyses, the 
OS difference was smaller but still statistically significant (HR 0.63, 95% CI 0.46 to 
0.83, P=0.0015), with a median OS time of 20.9 months (95% CI 18.5 to 29.6) versus 
12.6 months (95% CI 11.4 to 15.2) (Fig. 2B). As demonstrated in the IPTW-adjusted 
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Kaplan-Meier plot (Fig. 2B), there was no impact of CN on OS probabilities at 3 
months (CN versus NCN: 95.3% versus 95.2%, P=0.97), at 6 months (84.6% versus 
81.2%, P=0.67), and 9 months (71.3% versus 67.9%, P=0.70). A clinically relevant 
OS benefit in favour of the CN group first appeared after 12 months (65.9% versus 
51.9%, P=0.11) and was statistically significant at 18 months (59.2% versus 34.0%, 
P=0.005) and 24 months (44.2% versus 21.8%, P=0.004). The 3-month landmark 
IPTW-adjusted analysis demonstrated little impact of immortal time bias on treatment 
effect (HR 0.64, 95% CI 0.48 to 0.86, P=0.004). At adjusted 12-months landmark 
analysis that considered only patients alive at that landmark point, CN was 
associated with a 44% decreased relative risk of death (HR 0.56, 95% CI 0.37 to 
0.85, P=0.006). 
Using interaction term analyses, we tested whether type of treatment (CN versus 
NCN) interacted with baseline predictors of overall mortality. IPTW-adjusted HR are 
presented in Figure 3. In these analyses, the beneficial effect of CN increased in 
patients with better KPS (P=0.06), in women (P=0.03), and in patients with 
thrombocytosis (P=0.01). The effect of CN did not differ according to the type of TT 
(P=0.47). 
 
Sensitivity analysis 
Magnitudes of the joint bounding factor for different combinations of the treatment-
confounder association ORCN-U and the mortality-confounder association HROM-U are 
shown in Table 2. For insignificance (yellow) or the opposite effect of CN (red), ORCN-
U and HROM-U would need to meet specific estimates. The odds of receiving CN in the 
presence of a given unmeasured confounder (e.g. small volume metastatic disease) 
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would need to increase, while the overall mortality would need to decrease in the 
presence of the same confounder. In a second set of sensitivity analysis, the cohort 
was restricted to patients with clear cell subtype. Propensity scores were re-
estimated for this subset, and the final models showed comparable results to the 
initial analysis without altering any conclusion. In final set of sensitivity analysis, we 
fitted a multivariable Cox model with baseline and treatment variables, including the 
effect of advanced line treatment. In this analysis, the beneficial effect of CN was 
confirmed (HR 0.68, P=0.043, Table 3).  
 
 
DISCUSSION 
In this retrospective study, we evaluated the prognostic effect of CN in patients with 
synchronous mRCC that subsequently received TT. In our cohort, CN had a 
statistically significant effect on overall mortality. Patients with a good KPS, women 
and those with thrombocytosis may benefit from CN and could represent the target 
population for future randomised trials.  
The observed benefit in overall mortality for patients treated with CN is in line with 
other retrospective studies [8, 9], although our HR was slightly more conservative. 
Recently, Petrelli et al. [15] attempted a meta-analysis of retrospective studies and 
reported a pooled HR of 0.46. However, as data quality was generally limited in these 
non-randomised observational studies, data from the pooled analysis were of limited 
quality as well. Further analyses from our study suggest that the beneficial effect of 
CN on mortality increases with increasing incremental survival time. Indeed, we did 
not find a difference in OS in the first 12 months of survivorship. Comparably, in 
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adjusted analyses by Heng et al. [9], there was no statistically significant difference 
for patients who lived <3 months, 6 and 12 months; whereas there was a survival 
advantage for those patients estimated to survive longer. In contrast, in a large 
retrospective study from the National Cancer Database [8], statistical significance 
was obtained earlier than 12 months, but the absolute benefit was only 0.7 to 1.8 
months. Furthermore, this study included almost 13,000 patients, which enabled the 
detection of very small statistically significant differences that were not present in 
smaller studies. Despite providing the largest sample size to date, this study did not 
account for performance status, laboratory data, IMDC prognostic group, or type of 
TT, as these data were not available in this registry.  
This, however, does not mean that patients with an estimated survival of <12 months 
do not benefit from a CN. First, CN has clear role in symptom palliation, i.e. in 
patients with intractable pain, bleeding, uncontrolled hypertension, and symptoms 
due to paraneoplastic syndromes. Second, our interaction term analysis 
demonstrated an oncological benefit for certain subgroups, such as patients with 
thrombocytosis. Although generally considered as a group with dismal prognosis [13], 
CN may improve OS in this subgroup even though it may still be less than 12 
months. The absolute benefit is minor and has to be balanced against the period of 
hospitalization and postoperative recovery. Further, with the low number of patients 
and the fairly large confidence interval, this finding has to be treated with caution. It is 
possible that it represents a statistical artefact rather than a true clinically relevant 
association. Similar conclusions can be drawn for gender and KPS, which represent 
the other two variables showing a clinically relevant interaction with CN. KPS, 
however, was previously identified as a predictor of outcomes. In a study by Heng et 
al. [9], the HR for CN was 0.53 in patients with KPS >80 and 0.70 for patients with 
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KPS <80, although no testing for heterogeneity or interaction was performed. KPS 
may therefore be a critical factor that determines the effect of CN, but further 
validation studies are necessary.  
Propensity score methods are often used to remove the effects of measured 
confounders in observational studies, including propensity score matching, covariate 
adjustment using propensity scores, and IPTW. IPTW creates a synthetic sample in 
which the distribution of measured baseline covariates is independent of treatment 
assignment [16] and allows relatively unbiased estimates of average treatment 
effects [17]. Of note, the design phase of the study is separated from the analysis 
phase, which is more comparable to randomised experiments [18]. IPTW serves to 
weight all groups up to the full sample [19], which is certainly an advantage over 
traditional matched pairs analyses. In urological cancer research, IPTW-adjusted 
analyses have been popularised by Seisen et al. [11] Using a similar approach, we 
were able to calculate a HR of 0.63 (95% CI 0.46 to 0.83) in favour of CN, which 
provided us with a more conservative estimate than data from unweighted analyses 
(HR 0.46, 95% CI 0.34 to 0.62). We contend that in the setting of mRCC with many 
possible confounders, a more conservative approach is preferable. 
As propensity scores can only adjust for measured confounders, unmeasured 
confounding must be addressed using distinct sensitivity analyses. Groups may differ 
with regards to these unmeasured confounders, which may subsequently impact the 
outcome measure [20]. We used sensitivity analyses according to Ding and 
VanderWheele, which has the advantage of making no assumptions about the 
structure of the unmeasured confounder and to provide stronger conclusions than 
traditional Cornfield conditions [14]. We show that, under certain circumstances, an 
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unmeasured confounder would render the effect of CN insignificant, if there are 
imbalances in the odds for receiving a CN (yellow and red area in Table 2).  
The role of CN in the era of immuno-oncology is unclear at present. In the 
CheckMate 025 trial, more than 85% of patients had prior CN, but the impact of CN 
on outcomes was not analysed [21]. Cytoreductive surgery may be an important 
cornerstone in the multidisciplinary management of these patients, comparable to 
patients who received cytokines. The current study showed an OS benefit if patients 
received nivolumab or cabozantinib in the advanced line setting (Table 3). Further, 
the analysis reinforced the concept that there are multiple baseline (liver and node 
metastasis, thrombocytosis, KPS) and treatment characteristics (advanced line 
treatment) that dictate OS, and CN may be one of them. Due to low numbers of 
patients, it was not possible to analyse the role of CN in patients receiving nivolumab. 
As a first step, an analysis of clinical trial data of CheckMate 025 may provide a 
hypothesis, and IPTW adjustment may be used for this purpose.  
In randomised controlled trials, the survival time is generally calculated from the date 
of randomisation, which is not available in retrospective observational studies. 
Interestingly, there has been no consensus on how to define this starting point. While 
some groups used the time from the initiation of first-line targeted therapy [9, 22], 
Hanna et al. [8] employed the date of diagnosis, and others did not specify the exact 
method. Using the date from starting first-line treatment gives an artificial survival 
advantage of weeks to months to the group of patients who did not undergo CN, as 
the period of nephrectomy and subsequent recovery is not included. Therefore, the 
authors of the present manuscript used the time of diagnosis, which may provide a 
better estimate of patient survival and may be more close to the date of 
randomisation. 
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The current study is limited by a single-institution experience and its retrospective 
design. Subgroup analyses were limited by sample size. For example, in contrast to 
clear cell mRCC, the 95% CI of the HR for non-clear cell included 1.00. However, the 
P-value for the interaction test insignificant, which could be related to statistical power 
problems. Larger studies focusing on non-clear cell mRCC should address the 
question if CN is beneficial in this subgroup.  As this was an analysis of an oncology 
database, the overall number of patients diagnosed with mRCC and the number of 
patients who received CN and then did not receive TT because of CN-related 
morbidity, progressive disease or other reasons is unknown. Specifically, CN-related 
morbidity may be substantial, but it was not possible to account for that. In the British 
Association of Urological Surgeons nephrectomy audit, the 30-day mortality was 
1.8%, 24.1% required perioperative blood transfusion and 8% had postoperative 
complications of Clavien–Dindo grade ≥ III [23]. Finally, selection bias and 
unmeasured differences between groups are a major problem in every retrospective 
study dealing with complex diseases such as mRCC. Several baseline parameters 
such as primary tumour volume (i.e. measured by size, local T stage on imaging) are 
important parameters which likely affected management but were not analysed, as 
no imaging review was performed. We attempted to address selection bias by 
performing IPTW-adjusted analyses according to many baseline variables and 
unmeasured confounding by sensitivity analysis. Nonetheless, residual unmeasured 
confounding may have impacted the effect of CN. We recognise the limitations of 
both statistical approaches and that they cannot replace randomisation.  
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CONCLUSIONS 
IPTW-adjusted analysis of our patient cohort suggests that CN improves OS of 
patients with synchronous mRCC treated with TT. On the whole, the survival 
difference appears after 12 months. Specific subgroups may benefit from CN, and 
these subgroups warrant further investigation in prospective trials. 
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FIGURE LEGENDS 
Figure 1 Temporal trends in utilisation of cytoreductive nephrectomy in 261 
patients with synchronous metastatic RCC treated at Cambridge 
University Hospitals. There was a significant decline in the use of 
cytoreductive nephrectomy between 2006/2007 and 2016/2017 by 
11.5 % every two years (95% CI -19.7 to -2.5, P<0.001).  
Figure 2 Unadjusted (A) and inverse probability of treatment weighting-
adjusted (B) Kaplan-Meier estimates of overall survival in patients 
who underwent cytoreductive nephrectomy versus no cytoreductive 
nephrectomy for synchronous metastatic renal cell carcinoma. 
Figure 3 Forest plot depicting inverse probability of treatment weighting-
adjusted hazard ratios of overall mortality of cytoreductive 
nephrectomy versus no cytoreductive nephrectomy according to 
baseline clinical variables. Due to small numbers, the subgroups of 
patients with brain metastasis and an interval to TT >12 months were 
not analysed.  
 
Figure1
Figure2A
Figure2B
Figure3
Table 1 
Baseline characteristics for 261 patients who received targeted therapies with (CN) or without cytoreductive nephrectomy 
(NCN) for synchronous metastatic renal cell carcinoma in the unweighted and weighted cohort of the Cambridge Oncology 
Registry. TT, targeted therapy. 
  Unweighted cohort     IPTW-weighted cohort 
  Overall No CN CN 
Std 
difference     No CN CN 
Std 
difference 
Number of patients - n (%) 261 (100) 164 (62.8) 97 (37.2) -     - - - 
Age - mean (SD) 62.2 (11.2) 64.4 (9.9) 58.6 (12.4) 0.512     62.36 (9.39) 62.2 (9.65) 0.017 
Male gender - n (%) 181 (69.3) 116 (70.7) 65 (67.0) 0.08     44.9 (69.1) 44.4 (68.1) 0.023 
Lung metastasis - n (%) 196 (75.1) 124 (75.6) 72 (74.2) 0.032     46.8 (72.0) 48.6 (74.5) 0.057 
Liver metastasis - n (%) 34 (13.0) 25 (15.2) 9 (9.3) 0.183     6.5 (10.0) 7.5 (11.5) 0.048 
Brain metastasis - n (%) 10 (3.8) 9 (5.5) 1 (1.0) 0.253     1.1 (1.7) 1 (1.5) 0.015 
Node metastasis - n (%) 107 (41.0) 75 (45.7) 32 (33.0) 0.263     24.1 (37.1) 24.5 (37.6) 0.01 
Bone metastasis - n (%) 89 (34.1) 69 (42.1) 20 (20.6) 0.475     17.5 (26.9) 16.4 (25.1) 0.041 
Number of metastatic sites - n (%)       0.738         0.032 
  One 97 (37.2) 44 (26.8) 53 (54.6) 
 
    30 (46.3) 29.3 (45.0)   
  Two 103 (39.5) 67 (40.9) 36 (37.1) 
 
    27.5 (42.3) 27.9 (42.8)   
  Three or more 61 (23.4) 53 (32.3) 8 (8.2)       7.4 (11.4) 8 (12.3)   
Subtype - n (%)       0.349     
  
0.041 
  Clear cell 203 (77.8) 123 (75.0) 80 (82.5) 
 
    53.7 (82.7) 53.6 (82.2)   
  Non-clear cell 39 (14.9) 24 (14.6) 15 (15.5) 
 
    9.7 (14.9) 9.6 (14.7)   
  Unclassified/unknown 19 (7.3) 17 (10.4) 2 (2.1)       1.6 (2.4) 2 (3.1)   
Anaemia - n (%) 141 (54.0) 103 (62.8) 38 (39.2) 0.486     30 (46.2) 29.3 (44.9) 0.027 
Neutrophilia - n (%) 62 (23.8) 49 (29.9) 13 (13.4) 0.408     10.8 (16.6) 11.5 (17.6) 0.028 
Hypercalcaemia - n (%) 47 (18.0) 33 (20.1) 14 (14.4) 0.151     9.6 (14.8) 11.1 (17.0) 0.06 
Thrombocytosis - n (%) 68 (26.1) 51 (31.1) 17 (17.5) 0.32     13.2 (20.3) 14 (21.5) 0.029 
Interval to TT <12 months - n (%) 245 (93.9) 158 (96.3) 87 (89.7) 0.263     61 (93.8) 59.6 (91.4) 0.092 
KPS <80% - n (%) 84 (32.2) 62 (37.8) 22 (22.7) 0.334     18.7 (28.7) 19.6 (30.0) 0.027 
IMDC prognostic group - n (%)       0.522   
 
    0.092 
  Favourable 6 (2.3) 1 (0.6) 5 (5.2) 
 
  
 
1 (1.5) 1.5 (2.3)   
  Intermediate 134 (51.3) 73 (44.5) 61 (62.9) 
 
  
 
39.7 (61.1) 37.3 (57.2)   
  Poor 121 (46.4) 90 (54.9) 31 (32.0)       24.3 (37.4) 26.4 (40.5)   
 
Table 2 
Magnitudes of the joint bounding factor for various combinations of the odds of receiving 
cytoreductive nephrectomy and the hazard of overall mortality in the presence of unmeasured 
confounders. Blue, gold, and red areas correspond to a joint bounding factor correspond to 
significant, nonsignificant, and opposite treatment effect of cytoreductive nephrectomy. 
 
  
Table 3 
Multivariable Cox proportional hazards model predicting overall mortality. 
 
Variable HR 95% CI P value 
Age 1.00 0.99 - 1.02 0.56 
Male gender 0.87 0.64 - 1.19 0.4 
Lung metastasis 0.97 0.66 - 1.42 0.87 
Bone metastasis 1.28 0.89 - 1.85 0.19 
Liver metastasis 1.73 1.13 - 2.64 0.012 
Lymph node metastasis 1.57 1.14 - 2.15 0.006 
Brain metastasis 0.88 0.39 - 2.00 0.77 
Anaemia 1.33 0.98 - 1.82 0.07 
Hypercalcaemia 0.82 0.55 - 1.22 0.34 
Thrombocytosis 1.54 1.08 - 2.20 0.016 
KPS <80 1.71 1.24 - 2.37 0.001 
Interval to TT >12 months 1.71 0.93 - 3.16 0.087 
Subtype    
   Clear cell 1.00   
   Non-clear cell 1.45 0.96 - 2.20 0.074 
   Unclassified/unknown 0.82 0.45 - 1.48 0.51 
Advanced line treatment (>first line)    
   No 1.00   
   Yes, not nivolumab/cabozantinib 0.60 0.44 - 0.83 0.002 
   Yes, nivolumab/cabozantinib 0.24 0.10 - 0.55 <0.001 
Cytoreductive nephrectomy 0.68 0.48 - 0.99 0.043 
 
  
 
